Cargando…
Levosimendan in Europe and China: An Appraisal of Evidence and Context
The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the...
Autores principales: | Kong, Xiangqing, Hu, Xinqun, Hua, Baotong, Fedele, Francesco, Farmakis, Dimitrios, Pollesello, Piero |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591618/ https://www.ncbi.nlm.nih.gov/pubmed/34815750 http://dx.doi.org/10.15420/ecr.2021.41 |
Ejemplares similares
-
Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan
por: Agostoni, Piergiuseppe, et al.
Publicado: (2019) -
Preoperative Levosimendan therapy reduces postoperative right ventricular failure in patients undergoing left ventricular assist device implantation
por: Sugimura, Yukiharu, et al.
Publicado: (2023) -
Prevalence of left ventricular dysfunction in a UK community sample of very old people: the Newcastle 85+ study
por: Yousaf, Fahad, et al.
Publicado: (2012) -
Effect of Left Ventricular Assist Device Implantation and Heart Transplantation on Habitual Physical Activity and Quality of Life()
por: Jakovljevic, Djordje G., et al.
Publicado: (2014) -
The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective
por: Griffiths, A, et al.
Publicado: (2014)